You are here
Rheumatoid Arthritis Drugs Market to Record a CAGR of Approx 10.5% During 2019-2024
DUBLIN, April 1, 2019 /PRNewswire/ -- The "Rheumatoid Arthritis Drugs Market- Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.
The global rheumatoid arthritis drugs market is expected to register a CAGR of nearly 10.5% during the forecast period, 2019-2024
The key factors propelling the growth of the rheumatoid arthritis drugs market are the launch of new biosimilars, rising prevalence of arthritis, and an increase in the acceptance of biopharmaceuticals.
The major factors that fuel the growth of the market are the rising incidence of rheumatoid arthritis and the increasing geriatric population. It usually affects the geriatric population, and the prevalence is seen higher in females as compared to males. Therefore, with the increasing geriatric population, the market is expected to experience growth in the coming years.
There are also several therapeutics and medications that have been developed in the recent years, to treat the symptoms of rheumatoid arthritis. Rheumatoid arthritis drugs management is generally associated with a high cost. Most commonly used drugs are disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologic drugs. Thus biologics account for a prominent market share, in terms of revenue, due to the considerably high cost of these medicines. However the costs of rheumatoid arthritis drugs and NSAIDs are less than biologics.
Thus, growing availability and awareness of safer drugs are anticipated to increase the global rheumatoid arthritis drugs market.
Key Market Trends
NSAIDs Segment by Drug Class is Expected to be the Largest Segment During the Forecast Period
NSAIDs are being widely utilized for the symptomatic treatment of rheumatic disorders. DMARDs are also considered as the gold standard for the treatment of moderate to severe rheumatoid arthritis. Unlike conventional DMARDs, such as NSAIDs, which simply give symptomatic relief, biologic drugs are more efficient in the management of rheumatoid arthritis.
Asia-Pacific is Witnessing High Growth and is Expected to Follow the Same Trend Over the Forecast Period
The Asia-Pacific market is projected to witness high growth during the forecast period, due to increasing healthcare expenditure. Moreover, the low cost of manufacturing in China and India has resulted in the rise in the production facilities, attracting pharmaceutical and biotechnological giants to the Asia-Pacific region from across the world. The increase in the incidence of rheumatoid arthritis disease is also expected to fuel the market in the region during the forecast period.
A majority of rheumatoid arthritis drug products are being manufactured by key players. The market leaders in this industry have established their position in the market, and these manufacturers have a wide product range to offer and have an extensive distribution system across the world. Additionally, the emerging markets in the Asia-Pacific region are witnessing the entry of small players.
Key Topics Covered
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Launch of New Biosimilars
4.2.2 Rising Prevalence of Arthritis
4.2.3 Increase in the Acceptance of Biopharmaceuticals
4.3 Market Restraints
4.3.1 Patent Expiration of Blockbuster Drugs
4.3.2 Alternative Treatment Options
4.4 Porter's Five Forces Analysis
5 Market Segmentation
5.1 By Type of Molecule
5.2 By Drug Class
5.2.1 Non-steroidal Anti-inflammatory Drugs (NSAIDs)
5.2.4 Other Drug Classes
5.3 By Sales Channel
5.3.2 Over-the-counter (OTC)
5.4.1 North America
5.4.4 Middle East & Africa
5.4.5 South America
6 Competitive Landscape
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Amgen Inc.
6.1.3 Bayer AG
6.1.4 Boehringer Ingelheim GmbH
6.1.5 Bristol-Myers Squibb Company
6.1.6 Celgene Corporation
6.1.7 F. Hoffmann-La Roche AG
6.1.8 Johnson & Johnson
6.1.9 Merck & Co. Inc.
6.1.10 Novartis AG
7 Market Opportunities and Future Trends
For more information about this report visit https://www.researchandmarkets.com/r/hycepb
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets